NO20056174L - Levering av et aktivt legemiddel til den posteriore del av oyet via subkonjunktiv eller periokular levering av et prolegemiddel - Google Patents

Levering av et aktivt legemiddel til den posteriore del av oyet via subkonjunktiv eller periokular levering av et prolegemiddel

Info

Publication number
NO20056174L
NO20056174L NO20056174A NO20056174A NO20056174L NO 20056174 L NO20056174 L NO 20056174L NO 20056174 A NO20056174 A NO 20056174A NO 20056174 A NO20056174 A NO 20056174A NO 20056174 L NO20056174 L NO 20056174L
Authority
NO
Norway
Prior art keywords
delivery
active drug
periocular
prodrug
posterior portion
Prior art date
Application number
NO20056174A
Other languages
English (en)
Norwegian (no)
Inventor
Orest Olejnik
Patrick M Hughes
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of NO20056174L publication Critical patent/NO20056174L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20056174A 2003-07-10 2005-12-23 Levering av et aktivt legemiddel til den posteriore del av oyet via subkonjunktiv eller periokular levering av et prolegemiddel NO20056174L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/617,468 US20050009910A1 (en) 2003-07-10 2003-07-10 Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
PCT/US2004/021938 WO2005011741A2 (fr) 2003-07-10 2004-07-07 Administration d'un medicament actif dans la partie posterieure de l'oeil, via adminstration sous-conjonctivale ou perioculaire d'un promedicament

Publications (1)

Publication Number Publication Date
NO20056174L true NO20056174L (no) 2006-01-25

Family

ID=33564972

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056174A NO20056174L (no) 2003-07-10 2005-12-23 Levering av et aktivt legemiddel til den posteriore del av oyet via subkonjunktiv eller periokular levering av et prolegemiddel

Country Status (16)

Country Link
US (2) US20050009910A1 (fr)
EP (1) EP1644047A2 (fr)
JP (1) JP2007528851A (fr)
KR (1) KR20060033008A (fr)
CN (1) CN1882362A (fr)
AU (1) AU2004260645B2 (fr)
BR (1) BRPI0412496A (fr)
CA (1) CA2531753A1 (fr)
IL (1) IL172583A (fr)
MX (1) MXPA06000408A (fr)
NO (1) NO20056174L (fr)
NZ (2) NZ544027A (fr)
PL (1) PL380169A1 (fr)
RU (1) RU2353393C2 (fr)
WO (1) WO2005011741A2 (fr)
ZA (1) ZA200510129B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
CN1889954A (zh) * 2003-12-02 2007-01-03 阿勒根公司 用类维生素a预防和/或减轻光受体变性的方法
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
CA2601278C (fr) * 2004-03-17 2014-06-10 Lars Michael Larsen Prevention de la retinopathie par inhibition du cycle visuel
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
WO2005107708A1 (fr) 2004-04-30 2005-11-17 Allergan, Inc. Implants d'inhibiteurs de tyrosine kinase intravitreens, biodegradables
AU2011211380B9 (en) * 2004-04-30 2014-05-08 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitor implants
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
WO2006043965A1 (fr) * 2004-10-14 2006-04-27 Allergan, Inc. Compositions ophtalmiques therapeutiques contenant des excipients sans danger pour la retine et leurs methodes
US8246949B2 (en) * 2004-10-27 2012-08-21 Aciont, Inc. Methods and devices for sustained in-vivo release of an active agent
ES2616296T3 (es) * 2005-12-02 2017-06-12 (Osi) Eyetech, Inc. Micropartículas de liberación controlada
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) * 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
US20070280902A1 (en) 2006-06-01 2007-12-06 Laura Rabinovich-Guilatt Method for treating eye disease or conditions affecting the posterior segment of the eye
EP2432453A2 (fr) * 2009-05-20 2012-03-28 Ranbaxy Laboratories Limited Solutions de rétinoïdes topiques
US10022348B2 (en) 2009-05-20 2018-07-17 Sun Pharmaceutical Industries Limited Topical solution of isotretinoin
WO2011106702A2 (fr) 2010-02-25 2011-09-01 The Johns Hopkins University Délivrance prolongée d'agents thérapeutiques à un compartiment oculaire
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
JP5996544B2 (ja) 2010-10-15 2016-09-21 クリアサイド・バイオメディカル・インコーポレーテッドＣｌｅａｒｓｉｄｅ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ 眼球アクセス用装置
WO2012109363A2 (fr) 2011-02-08 2012-08-16 The Johns Hopkins University Vecteurs géniques pénétrant le mucus
EP2804632B1 (fr) 2012-01-19 2019-09-18 The Johns Hopkins University Nanoparticules présentant une pénétration mucosale améliorée
JP6138904B2 (ja) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
ES3055223T3 (en) 2012-05-03 2026-02-10 Alcon Inc Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2013256008B2 (en) 2012-05-04 2016-02-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
MX373894B (es) 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
BR112015027762A2 (pt) 2013-05-03 2017-08-29 Clearside Biomedical Inc Aparelho e métodos para injeção ocular
WO2014197317A1 (fr) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Appareil et procédés pour une administration de médicament à l'aide de multiples réservoirs
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
EP3099290A1 (fr) 2014-01-28 2016-12-07 Allergan, Inc. Formulations topiques de rétinoïdes, et procédés d'utilisation
WO2015127368A1 (fr) 2014-02-23 2015-08-27 The Johns Hopkins University Formulations microbicides hypotoniques et leurs méthodes d'utilisation
EP3157598A4 (fr) 2014-06-20 2018-05-16 Clearside Biomedical, Inc. Canule à diamètre variable et procédés de commande de profondeur d'insertion pour administration de médicaments
KR20240126072A (ko) 2015-01-27 2024-08-20 더 존스 홉킨스 유니버시티 점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035408A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés pour le traitement de troubles immunitaires et inflammatoires
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
EP3452165A1 (fr) 2016-05-02 2019-03-13 Clearside Biomedical, Inc. Systèmes et méthodes pour l'administration de médicaments par voie ophtalmique
EP3454856B1 (fr) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
SG11201811491YA (en) 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
IL305537B2 (en) 2016-08-12 2025-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a needle for administering a drug
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP3650045B1 (fr) 2017-07-04 2024-11-13 Daiichi Sankyo Company, Limited Médicament contre une maladie dégénérative de la rétine associée à une dégénérescence des photorécepteurs
EP3773576A4 (fr) 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Liants de céréblon pour la dégradation d'ikaros
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
EP3866773B1 (fr) 2018-10-16 2024-08-28 Georgia State University Research Foundation, Inc. Promédicaments de monoxyde de carbone pour le traitement de troubles médicaux
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
CN115362162A (zh) 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
TW202146412A (zh) 2020-03-05 2021-12-16 美商Ｃ４醫藥公司 用於標靶降解brd9之化合物
KR20230012547A (ko) 2020-05-19 2023-01-26 쥐원 쎄라퓨틱스, 인크. 의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5275820A (en) * 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
WO1995003009A1 (fr) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Methode de traitement de la degenerescence maculaire
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5420120A (en) * 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
NZ283658A (en) * 1994-04-04 1999-09-29 William R Freeman Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides)
JP4259610B2 (ja) * 1994-04-08 2009-04-30 キューエルティー・ユーエスエイ・インコーポレーテッド 液体デリバリー組成物
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5718922A (en) * 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
US5675033A (en) * 1995-06-06 1997-10-07 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
IL140899A0 (en) * 1998-07-17 2002-02-10 Skyepharma Inc Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof
US6017938A (en) * 1998-07-28 2000-01-25 Bershad; Susan Short contact treatment for acne
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
AU6815901A (en) * 2000-06-02 2001-12-17 Zycos Inc Delivery systems for bioactive agents
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
JP4061015B2 (ja) * 2000-10-30 2008-03-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 レチノイン酸レセプターアゴニスト作用を有する薬剤含有組成物
US6673802B2 (en) * 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
NZ528994A (en) * 2001-04-26 2006-02-24 Control Delivery Sys Inc Sustained release drug delivery system containing codrugs
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7381426B2 (en) * 2002-01-24 2008-06-03 Southwest Research Institute Targeted delivery of bioactive factors to the systemic skeleton
WO2004028477A2 (fr) * 2002-09-29 2004-04-08 Surmodics, Inc. Procede d'administration sub-retinienne d'agents therapeutiques comprenant des steroides, procede servant a concentrer une action pharmacodynamique au niveau de la choroide et de la retine et procedes associes servant a traiter et/ou a prevenir des maladies retiniennes

Also Published As

Publication number Publication date
ZA200510129B (en) 2007-02-28
IL172583A (en) 2011-02-28
EP1644047A2 (fr) 2006-04-12
WO2005011741A2 (fr) 2005-02-10
US20120157499A1 (en) 2012-06-21
US20050009910A1 (en) 2005-01-13
MXPA06000408A (es) 2006-03-17
IL172583A0 (en) 2006-04-10
KR20060033008A (ko) 2006-04-18
AU2004260645B2 (en) 2010-03-11
RU2006104983A (ru) 2006-06-27
PL380169A1 (pl) 2007-01-08
RU2353393C2 (ru) 2009-04-27
WO2005011741A3 (fr) 2005-04-14
JP2007528851A (ja) 2007-10-18
CN1882362A (zh) 2006-12-20
CA2531753A1 (fr) 2005-02-10
AU2004260645A1 (en) 2005-02-10
BRPI0412496A (pt) 2006-09-19
NZ544027A (en) 2010-07-30
NZ582376A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
NO20056174L (no) Levering av et aktivt legemiddel til den posteriore del av oyet via subkonjunktiv eller periokular levering av et prolegemiddel
EP4491229A3 (fr) Arn codant administré dans l'espace suprachoroïdien dans le traitement de maladies ophtalmiques
EA201071413A1 (ru) Способ и композиция для лечения повышения внутриглазного давления и глаукомы
BRPI0819081A8 (pt) Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
WO2006071548A3 (fr) Analogues d'aminopyrazine servant a traiter le glaucome et d'autres maladies ou etats medies par rho kinase
BR0309623A (pt) Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas
RU2012110324A (ru) Способы лечения хронического нейрогенного воспаления с помощью модифицированного клостридиального токсина
US20130310327A1 (en) Histatin for Corneal Wound Healing and Ocular Surface Disease
WO2002009702A8 (fr) Methode de reduction de la pression intraoculaire avec des derives d'indole
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
AU2017261303A1 (en) Ophthalmic compositions
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
MX2024003580A (es) Metodos de tratamiento de enfermedades inflamatorias oculares.
WO2019010301A8 (fr) Traitement de cardiopathies par inhibition de l'action des protéines d'ancrage aux protéines kinases a (makap) du muscle
Sarkis et al. Challenging glaucoma with emerging therapies: an overview of advancements against the silent thief of sight
WO2009003694A3 (fr) Procédé de traitement de maladies liées à un dysfonctionnement mitochondrial
EP4691493A3 (fr) Compositions pour le traitement des maladies oculaires
MX2023001599A (es) Composicion farmaceutica que comprende un conjugado de accion prolongada del triple agonista del receptor de glucagon/glp-1/gip.
EA202000347A1 (ru) ПРОТИВО-SARS-CoV-2 ВИРУСНОЕ СРЕДСТВО АНТИПРОВИР
EP3085371A1 (fr) Dérivés de parthénolide et leur utilisation dans le traitement de lésions axoniques
WO2023150790A3 (fr) Nouveaux inhibiteurs mpro du sars-cov-2 hautement sélectifs
MX2024003072A (es) Tratamiento de la degeneracion retiniana.
WO2022084561A3 (fr) Composés de microarn-29, compositions et utilisations thérapeutiques
BR112023023702A2 (pt) Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga
MY145266A (en) Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application